AtaiBeckley (ATAI) Long-Term Deferred Tax (2020 - 2025)
AtaiBeckley (ATAI) posted quarterly Long-Term Deferred Tax of $165.4 million for Q4 2025, up 992.24% year-over-year from $15.1 million in Q4 2024, and up 992.24% quarter-over-quarter from $15.1 million in Q4 2024.
Powered by 
Analysis
AtaiBeckley (ATAI) Long-Term Deferred Tax (2020 - 2025) Analysis & Trends
AtaiBeckley's Long-Term Deferred Tax history runs 2 years deep, the most recent figure standing at $165.4 million for Q4 2025.
- In Q4 2025, Long-Term Deferred Tax rose 992.24% year-over-year to $165.4 million; the TTM figure through Dec 2025 stood at $165.4 million (up 992.24% YoY), while the FY2025 annual figure was $165.4 million, up 992.24% from the prior year.
- Long-Term Deferred Tax for Q4 2025 stood at $165.4 million, up from $15.1 million in the prior quarter.
- Over five years, Long-Term Deferred Tax peaked at $8.6 million in Q4 2021 and troughed at $6.0 million in Q4 2020.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | AtaiBeckley | 1.61 Bn | 1.61 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 165.44 Mn |
| Dec 31, 2024 | 154.66 Mn |
| Dec 31, 2021 | 31.15 Mn |
| Dec 31, 2020 | 6.32 Mn |